Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2022-01-17 Capital/Financing Update
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Capital/Financing Update Classification · 1% confidence The document is titled "Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF" and provides specific figures regarding shares and cash held in a liquidity account as of December 31, 2021, along with transaction volumes executed between July 1st and December 31st, 2021. This content relates to the management of the company's own shares or capital structure, specifically concerning a liquidity agreement (often related to share buybacks or stabilization). This fits best under Capital/Financing Update (CAP) or Transaction in Own Shares (POS). Since it details the activity under a specific agreement governing share transactions (liquidity agreement), 'Transaction in Own Shares' (POS) is the most precise fit, as liquidity agreements are mechanisms for managing share price stability, often involving repurchases or sales of own stock. It is not a comprehensive financial report (IR/10-K) or a general announcement of a report (RPA).
2022-01-17 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is titled "Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF" (Semi-annual balance sheet of the liquidity contract between IPSEN and NATIXIS ODDO BHF) and reports on the status and transactions executed under a liquidity contract (market making/stabilization agreement) for the period July 1, 2021, to December 31, 2021. This type of regular reporting on share transactions, often related to market stabilization or liquidity provision, is a specific type of corporate action disclosure. It is not a standard financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It details transactions involving the company's own shares under a specific agreement, which aligns closely with the description of 'Transaction in Own Shares' (POS), although it is specifically about a liquidity contract rather than a general buyback program. However, given the options, POS covers transactions in own shares. If the document were purely about insider trading by directors, DIRS would apply. Since it details the activity of a liquidity provider acting on behalf of the company regarding its shares, POS is the most fitting category among the provided specific codes, as it relates directly to the company's share capital management activities. It is a specific report detailing share activity, not just an announcement of a report (RPA/RNS).
2022-01-17 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information relative to the total number of voting rights and shares composing the share capital." It provides a table detailing the total number of shares and the total number of voting rights as of a specific date (December 31, 2021), referencing French commercial code and the AMF (Autorité des Marchés Financiers). This content specifically relates to the calculation and reporting of voting rights associated with the share capital, which aligns most closely with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it is a periodic disclosure of voting power structure, even if not the final result of a specific vote. It is not an AGM presentation, a full annual report (10-K), or a director's dealing report.
2022-01-12 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de Commerce and AMF General Regulation) and provides a monthly update (as of December 31, 2021) detailing the total number of shares and the total gross and net voting rights. This content aligns perfectly with announcements regarding capital structure and voting rights, which is covered by the 'Share Issue/Capital Change' (SHA) definition, as it details the composition of the capital and voting rights, or potentially a specific regulatory filing. Given the specific nature of reporting total voting rights monthly, SHA is the most appropriate fit among the provided options, as it relates directly to the capital structure components (shares and voting rights). It is not a general earnings release (ER), interim report (IR), or a general regulatory filing (RNS) because it is highly specific to capital structure reporting.
2022-01-12 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing a threshold (Article L. 233-7 of the Commercial Code)'. This type of filing in French regulation specifically concerns notifications when an investor's stake in a company crosses certain ownership thresholds (like 5%). The text explicitly states that Parvus Asset Management Europe Limited crossed the 5% threshold of IPSEN SA's capital on December 21, 2021. This directly corresponds to the definition of a Major Shareholding Notification (MRQ). The document length is short (1386 chars), but it is the primary filing itself, not an announcement of a report.
2021-12-24 French
Inside Information / Operations of the issuer (acquisitions, sales...)
M&A Activity Classification · 1% confidence The document is a press release dated December 17, 2021, announcing an exclusive licensing agreement between Ipsen and GENFIT regarding the drug elafibranor for Primary Biliary Cholangitis (PBC). It details financial terms (€120m upfront, milestones, royalties, equity investment) and clinical trial status (Phase III ELATIVETM). This type of announcement, detailing a major strategic transaction (licensing/partnership) and associated financial/equity changes, fits best under the 'Capital/Financing Update' (CAP) category, as it involves significant capital structure changes (equity investment) and future financial obligations related to a major asset. While it involves R&D, the primary focus is the transaction itself. It is not a formal regulatory filing like a 10-K or an ER, nor is it a management change (MANG) or a dividend notice (DIV). It is a specific corporate action announcement.
2021-12-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.